GET DAILY SIGNALSWhy Is Johnson & Johnson (JNJ) Stock Down -1.22% Today?
Key Takeaways
- JNJ shares were down roughly 1.22% in afternoon trading, slipping to about $267.25 from a prior close of $270.56.
- The primary driver was broad-based selling across the healthcare and biotech sector, with large-cap pharmaceutical peers trading lower in sympathy.
- Profit-taking also pressured the stock after it touched a 52-week high of $282.02 in late October, leaving it ripe for a modest pullback.
- The move reflects sector rotation and cautious sentiment rather than a company-specific negative catalyst released today.
- Traders are watching whether healthcare selling stabilizes and whether JNJ can hold support near its recent trading range.
- For more detail on this ticker, explore its Price Targets, Earnings, and Forecast pages.
- Discover AI-driven trading strategies tailored to current market conditions on the Trending AI Robots page.
Opening Summary
Johnson & Johnson (JNJ), the New Brunswick, New Jersey-based healthcare conglomerate operating through its Innovative Medicine and MedTech segments, saw its stock decline about 1.22% during Tuesday's session. Shares traded near $267.25, down from the prior session's closing level of $270.56. The move lower came without a single dominant, company-specific headline, instead reflecting a broader pullback across the pharmaceutical and biotechnology complex as investors took profits in a sector that has enjoyed a strong run this year.
Sector-Wide Healthcare Selloff
The most immediate catalyst behind today's decline was weakness across the healthcare space. Large-cap pharmaceutical and biotech names broadly traded lower, with peers such as MRK, LLY, ABBV, and NVO all posting declines in sympathy. When heavyweight drugmakers move together, individual names like JNJ tend to follow, regardless of any firm-specific news. This sector-rotation dynamic, rather than a deterioration in Johnson & Johnson's fundamentals, appeared to be the main force driving shares lower.
Profit-Taking After a 52-Week High
The pullback also follows a period of notable strength. JNJ reached a 52-week high of $282.02 on October 30, capping a year in which the stock has delivered a substantial gain. After such a run, short-term traders frequently lock in gains, particularly when a sector experiences a down day. The stock's retreat from that high leaves it trading modestly below its recent peak, consistent with a normal consolidation phase rather than a fundamental break in the company's story.
Market Context and Trading Activity
The move aligned with sector-level weakness rather than a divergence driven by company-specific factors. Healthcare names were among the softer pockets of the market during the session, while the decline in JNJ remained relatively contained in magnitude. Volume in the prior session was elevated relative to its daily average, indicating active participation around the stock, and today's action suggested continued two-way trading as investors reassessed positions. Technically, the shares continue to hold comfortably above longer-term moving averages despite the intraday dip, reflecting the stock's overall uptrend.
What Comes Next for JNJ
Looking ahead, investors will monitor whether the healthcare sector's selling proves short-lived or marks the start of a broader rotation. JNJ delivered its third-quarter results in October, reporting sales growth alongside an adjusted earnings beat, though GAAP results were pressured by a large one-time charge tied to its proposed talc litigation resolution and recent deal activity. The company's next quarterly report is expected in late January. Key watch items include continued momentum in oncology and immunology products, the trajectory of the MedTech segment, and any further developments on litigation and portfolio prioritization. As with any pullback, the risk is that sector weakness persists, but the company's diversified healthcare portfolio provides a degree of insulation against single-product volatility.
Trending AI Robots
Tickeron's Trending AI Robots page highlights a curated selection of AI trading bots from a library of hundreds of strategies covering thousands of tickers. Because only the strongest performers under current market conditions are featured, the page offers a focused view of strategies that are working right now. Bots vary by strategy, timeframe, performance metrics, and traded symbols, giving traders a way to explore automated approaches suited to their own goals. Explore the page to see which AI-driven strategies are currently leading the market.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Serhii Bondarenko is an AI-focused trading strategist and financial markets analyst specializing in the development and application of AI trading bots and autonomous trading agents. His work combines technical analysis, fundamental analysis, and quantitative research to identify market patterns, forecast price movements, and analyze liquidity, volatility, and correlations across global stock markets. Serhii actively publishes market insights, forecasts, and trading frameworks on platforms such as Investing.com and Finextra, with a strong focus on AI-driven decision-making and next-generation algorithmic trading. His research aims to bridge the gap between traditional trading methodologies and advanced artificial intelligence, helping traders and investors navigate complex and rapidly evolving market conditions.
JNJ's RSI Indicator ascends from oversold territory
The RSI Indicator for JNJ moved out of oversold territory on October 07, 2026. This could be a sign that the stock is shifting from a downward trend to an upward trend. Traders may want to buy the stock or call options. The A.I.dvisor looked at 30 similar instances when the indicator left oversold territory. In 17 of the 30 cases the stock moved higher. This puts the odds of a move higher at 57%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on October 22, 2026. You may want to consider a long position or call options on JNJ as a result. In 33 of 84 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 39%.
The Moving Average Convergence Divergence (MACD) for JNJ just turned positive on October 21, 2026. Looking at past instances where JNJ's MACD turned positive, the stock continued to rise in 20 of 47 cases over the following month. The odds of a continued upward trend are 43%.
JNJ moved above its 50-day moving average on October 26, 2026 date and that indicates a change from a downward trend to an upward trend.
The 10-day moving average for JNJ crossed bullishly above the 50-day moving average on October 30, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 7 of 17 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 41%.
Following a +2.41% 3-day Advance, the price is estimated to grow further. Considering data from situations where JNJ advanced for three days, in 163 of 354 cases, the price rose further within the following month. The odds of a continued upward trend are 46%.
Bearish Trend Analysis
The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 7 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where JNJ declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 43%.
JNJ broke above its upper Bollinger Band on October 22, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Aroon Indicator for JNJ entered a downward trend on October 22, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron Profit vs. Risk Rating rating for this company is 3 (best 1 - 100 worst), indicating low risk on high returns. The average Profit vs. Risk Rating rating for the industry is 60, placing this stock better than average.
The Tickeron PE Growth Rating for this company is 7 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 26 (best 1 - 100 worst), indicating outstanding price growth. JNJ’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 37 (best 1 - 100 worst), indicating strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Seasonality Score of 49 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Valuation Rating of 76 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (7.673) is normal, around the industry mean (-1.476). P/E Ratio (30.992) is within average values for comparable stocks, (21.871). Projected Growth (PEG Ratio) (2.852) is also within normal values, averaging (5.738). Dividend Yield (0.020) settles around the average of (0.038) among similar stocks. P/S Ratio (6.658) is also within normal values, averaging (4.033).
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
an investment holding company with interests in health care products
Industry PharmaceuticalsMajor
Advertisement